AbCellera
AbCellera sells antibody discovery services and drug-candidate platforms to biotech and pharma customers, placing it in the compute pool's third-order beneficiaries because its demand depends on AI-driven drug research that runs on data-centre computing.
Checked against the company's own business description in its latest annual filing.
Latest disclosed
10-Q filed 2026-08-05 · period ending 2026-06-30
Pieces naming this company
None yet.
No price is shown: the Index is a map of what each company sells and where it sits, not a quote board.